Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 4;14(5):1118-1130.
doi: 10.1080/21645515.2018.1454570. Epub 2018 May 9.

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature

Paul Balmer  1 , Cynthia Burman  1 , Lidia Serra  1 , Laura J York  1
Affiliations
Review

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature

Paul Balmer et al. Hum Vaccin Immunother. .

Abstract

Colonization of the human nasopharyngeal tract by the bacterium Neisseria meningitidis is usually asymptomatic, but life-threatening meningococcal disease with a clinical presentation of meningitis, septicemia, or more rarely, gastrointestinal symptoms, can develop. Invasive meningococcal disease (IMD) can be fatal within 24 hours, but IMD is vaccine-preventable. Vaccines used to protect against IMD caused by 5 of the 6 most common serogroups (A, B, C, W, and Y) may also influence carriage prevalence in vaccinated individuals. Lower carriage among vaccinated people may reduce transmission to nonvaccinated individuals to provide herd protection against IMD. This article reviews observational and clinical studies examining effects of vaccination on N. meningitidis carriage prevalence in the context of mass vaccination campaigns and routine immunization programs. Challenges associated with carriage studies are presented alongside considerations for design of future studies to assess the impact of vaccination on carriage.

Keywords: Neisseria meningitidis; carriage; meningitis; meningococcal; vaccination.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention Meningococcal Disease. [accessed 2015October30] http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf.
    1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–210. doi:10.1016/S0140-6736(07)61016-2. PMID:1760480226123933 - DOI - PubMed
    1. Stoof SP, Rodenburg GD, Knol MJ, Rumke LW, Bovenkerk S, Berbers GA, Spanjaard L, van der Ende A, Sanders EA. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis. 2015;61(8):1281–92. doi:10.1093/cid/civ506. PMID:26123933 - DOI - PubMed
    1. Tirani M, Meregaglia M, Melegaro A. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. PLoS ONE. 2015;10(4):e0123383. doi:10.1371/journal.pone.0123383. PMID:25874805 - DOI - PMC - PubMed
    1. Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, Ladhani SN. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill. 2016;21(12):pii = 30175. doi:10.2807/1560-7917.ES.2016.21.12.30175. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources